linjc16/ctgov huggingface dataset:
The Influence of Compression Stockings on Skin's Barrier Function at Patients With Chronic Venous Disease

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to investigate if wearing of compression stockings influences the skin moisture. Conservative stockings are compared with urea containing compression stockings to find out if using urea prevents dehydration of the skin while wearing the urea compression stockings. Secondary aim was to find out if urea containing stockings increase the compliance to wear the compression stockings regulary by patients with diagnosed chronic venous insufficiency.

Official Title
-----------------
Prospective, Randomized and Explorative Controlled Study About Influences of Compression Stockings on Skin's Barrier Function at Patients With Chronic Venous Insufficiency

Conditions
-----------------
Venous Insufficiency

Intervention / Treatment
-----------------
* Device: urea contained compressing stockings
* Device: compressing stockings


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clincial diagnosis of chronic venous insufficiency Age: 18-80 years Patient's information and willingness to participate Exclusion Criteria: Age under 18 years Lower limp edema not caused by venous insufficiency Acute deep venous thrombosis Arterial occlusive disease Diabetes mellitus with neuropathy or peripheral arterial disturbance of perfusion immobile Patients Pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: urea contained compressing stockings|nan|
|Device: compressing stockings|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| skin moisture at day 0 and day 7 |  |  | 
| loss of water throughout epidermis at day 0 and day 7 |  |  | 
| throatiness of epidermis at day 0 and day 7 |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| compliance of patients at every day of intervention |  |  |
Remote Ischemic Preconditioning Before Abdominal Surgery

Study Overview
=================
Brief Summary
-----------------
Major abdominal surgeries are associated with perioperative cardiac morbidity of up to 10%. Ischemic preconditioning may have a protective effect. The purpose of this study is to find out remote ischemic conditioning by inflating a blood pressure cuff on the arm will have a protective effect.

Official Title
-----------------
Remote Ischemic Preconditioning Before Abdominal Surgery and the Prevalence of Perioperative Complications

Conditions
-----------------
Perioperative/Postoperative Complications

Intervention / Treatment
-----------------
* Procedure: Remote Ischemic Pre-conditioning
* Procedure: Control


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients undergoing abdominal surgery:large bowel, pancreatic and hepatic surgery Exclusion Criteria: Chronic inflammatory disease. Glyburide use before surgery.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: 1<br>Arm remote preconditioning | Procedure: Remote Ischemic Pre-conditioning<br>* Cuff placed on arm. Three 5- minute cycles of blood pressure cuff inflation: cuff is inflated to 200 mm Hg for 5 minutes followed by a 5-minute deflation (reperfusion.)<br>|
| Placebo Comparator: 2<br>Control group. | Procedure: Control<br>* Cuff placed on arm uninflated for 30 minutes.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cardiovascular Events: incidence of MI, TIA/stroke, death in both groups |  | One week | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Renal function deterioration in the first week after surgery | Baseline Creatinine levels will be compared to the highest creatinine levels noted in the first 7 days of hospitalization | One week | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Remote ischemic preconditioning, Abdominal surgery, Perioperative complications
Measurement of Outcome of Surgical Treatment in Patients With Acromegaly

Study Overview
=================
Brief Summary
-----------------
OBJECTIVES: I. Compare growth hormone (GH) levels at baseline and after glucose suppression measured with both a polyclonal radioimmunoassay and a highly sensitive immunoradiometric assay (IRMA) in patients with acromegaly and normal volunteers. II. Measure the levels of IGF-I and its binding protein, IGFBP-3, in these cohorts. III. Determine any correlation between levels of IGF-I and IGFBP-3 and GH suppressibility as assessed by sensitive IRMA. IV. Determine if patients who demonstrate biochemical features of mild GH excess are at risk for progression to active disease.

Detailed Description
-----------------
PROTOCOL OUTLINE: Blood samples are collected and assessed for growth hormone and IGF-I by polyclonal radioimmunoassay (RIA) and immunoradiometric assay (IRMA). Growth hormone is measured at baseline and 60, 90, and 120 minutes after a 100 g glucose drink. Serum glucose is measured at baseline and at 2 hours post dextrose administration by the glucose hexokinase method. Clinical scores are determined for headache, perspiration, fatigue, joint pain, and acne. Exams and tests may be repeated every 6 months for 2 years.

Conditions
-----------------
Acromegaly

Participation Criteria
=================
Eligibility Criteria
-----------------
PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- Diagnosis of acromegaly and treated with transsphenoidal surgery Biochemically and histologically confirmed growth hormone secreting tumor OR Healthy volunteers --Prior/Concurrent Therapy-- Surgery: See Disease Characteristics Greater than 6 months since prior surgery Other: At least 1 month since prior bromocriptine or octreotide --Patient Characteristics-- Performance status: Ambulatory Hepatic: No active hepatic disease Renal: No active renal disease Other: No diabetes mellitus No glucose intolerance Hypopituitarism allowed if on stable doses of replacement therapy

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
acromegaly, endocrine disorders, rare disease
Not Invasive Monitoring at Cardiac Recompensation

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to find out if data can be provided by external sensor technology which is suitable for controlling the therapy of patients with cardiac recompensation.

Conditions
-----------------
Cardiac Recompensation

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with acute or chronic cardiac decompensation with and without pulmonary oedema male and female patients aged at least 18 years Exclusion Criteria: pregnancy or breast feeding implanted pacemaker / CRT / ICD exept Medtronic OptiVol patients being unable to consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| suitable Data |  | 15 minutes per day and per patient, 3-5 days, at most 14 days |
NGAL Predictive Value of Acute Kidney Failure After Cardiac Surgery in Patients With Preoperative Chronic Kidney Failure

Study Overview
=================
Brief Summary
-----------------
Primary endpoint: To evaluate predictive value of plasmatic levels of Neutrophil Gelatinase Associated Lipocalin (NGAL) to reveal acute kidney failure after cardiac surgery in patients with preoperative chronic kidney failure Secondary endpoint is to obtain threshold values of NGAL.

Detailed Description
-----------------
(N/A)

Official Title
-----------------
Plasmatic Level of Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a Predictive Marker of Acute Kidney Failure in Patients With Preoperative Chronic Kidney Failure Undergoing Cardiac Surgery.

Conditions
-----------------
Preoperative KIDNEY FAILURE, CHRONIC, Postoperative KIDNEY FAILURE, ACUTE, Cardiac Surgical Procedures

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Renal clearance less than 60 mL/min Able to give written consent Elective valve surgery Elective CABG surgery Exclusion Criteria: Less than 18 years old Iodine injection within 3 days before surgery Iodine injection within 24 first postoperative hours preoperative infection evolutive cancer disease Refusal Pregnancy Unable to give written consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Neutrophil Gelatinase Associated Lipocalin (NGAL) level |  | From surgery to discharge from hospital | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
NGAL plasmatic level, Preoperative KIDNEY FAILURE, CHRONIC, Postoperative KIDNEY FAILURE, ACUTE, Cardiac Surgery Procedures
Treatment of Non-Hodgkin's Lymphoma With 90Y-hLL2 IgG

Study Overview
=================
Brief Summary
-----------------
The purpose of this trial is to determine the safety of a 90Y-radiolabeled, humanized (CDR-grafted) form of the LL2 monoclonal antibody in patients with Non-Hodgkin's lymphoma (NHL) at different dose levels.

Official Title
-----------------
Phase I/II Radioimmunotherapy of Non-Hodgkin's Lymphoma With Radiolabeled Humanized Immuno-LL2: Treatment With 90Y-hLL2 IgG

Conditions
-----------------
Non-Hodgkin's Lymphoma, Lymphoma, B-Cell

Intervention / Treatment
-----------------
* Drug: radiolabeled epratuzumab


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion: Histological or cytological diagnosis of B-cell lymphoma, and has failed at least one regimen of standard chemotherapy. (All histological grades of NHL will be eligible for this trial.) Measureable via CT, with at least one lesion > or = 1.5cm in one or both dimensions. (Splenic tumors in absence of other tumors will not qualify.) Radiological studies (ie - CT) must be performed within 4 weeks prior to study start. Acceptable tumor burden that will allow adequate follow-up and evaluation. Less that 25% bone marrow involvement, determined by bone marrow biopsy. Must observe the following washout periods: At least 4 weeks beyond any major surgery. At least 4 weeks beyond any radiation therapy to the index lesion, and has recovered from radiation-induced toxicity. At least 4 weeks beyond chemotherapy and/or immunotherapy. At least 2 weeks beyond corticosteriod(s) use and blood counts are with laboratory criteria. Must have Karnofsky score >70% (or equivalent, ECOG 0-2) with expected survival of at least 6 months. Serum creatinine < or = 1.5mg/dl or creatinine clearance > or = 50ml/min. Serum bilirubin < or = 2mg/dl. Hemoglobin > or = 10 g/dl; WBC > or = 3000/mm3; granulocyte count > or = 150/mm3; platelet count > or = 100,000/mm3 with out transfusions or cytokines for at least 30 days prior to study. Immunomedics ELISA assay of HahLL2 < 100ng/ml for those with prior history of monoclonal antibody infusions. Cognizant informed consent.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: radiolabeled epratuzumab|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
NHL, recurrent B-cell lymphoma
Focus Group Interviews of Patients With Permanent or Temporary Enterostomas

Study Overview
=================
Brief Summary
-----------------
The study seeks to gain knowledge about new and of alternative ways of organizing ostomy training based on informants' own experiences of life with a stoma. The study is designed and conducted as qualitative focus group interviews with three different groups of patients with enterostomas (5-8 in each group): a) people with permanent enterostoma due to cancer, 2) people with permanent enterostoma due to non-cancer and 3) people with a temporary ileostomy.

Detailed Description
-----------------
The study is investigating the perspective of the patients who have actually experienced having surgery and living with an enterostoma. By applying this method it is possible to gain access and in depth knowledge of complex issues including sensitive data. The dialogue with peers can lead to experiments and associations which might stimulate the informants to produce new insights within the individual and in the group. The interviews will be transcribed in full and analyzed with qualitative content analysis with a phenomenological and hermeneutical approach

Official Title
-----------------
Patient Perspectives on Living With an Enterostoma and Rehabilitation

Conditions
-----------------
Patient Perspective, Living With an Enterostoma, Mastery, Empowerment

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with permanent enterostoma due to cancer. Patients with permanent enterostoma due to other causes. Patients with temporary ileostomy. Exclusion Criteria: Patients with severe mental disorders. Patients who do not communicate in Danish. Patients with severe hearing impairment.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Educational elements and themes that will optimize rehabilitation and patient education | Illumination and discussion of informants´ perspective on rehabilitation and patient education will | up until 10 months from interview | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Identification of strategies for improving quality of life | Illumination and discussion of informants perspective on the influence of an enterostoma on their lives | up until 10 months from interview | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
quality of life, patient education, rehabilitation, focus group interview
D-Dimer and IPG for Recurrent Thrombosis (DIRECT)

Study Overview
=================
Brief Summary
-----------------
To simplify and improve the diagnostic approach to patients with clinically suspected recurrent DVT by determining whether the results of the combination of IPG and d-dimer testing, using a whole blood agglutination assay, can be used in the management of such patients.

Official Title
-----------------
D-Dimer and IPG for Recurrent Thrombosis (DIRECT) Study

Conditions
-----------------
Deep Vein Thrombosis, Pulmonary Embolism

Intervention / Treatment
-----------------
* Procedure: venogram


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: suspected deep vein thrombosis history of previous DVT or PE Exclusion Criteria: comorbid condition limiting survival to less than 6 months contraindication to contrast medium (allergy, renal dysfunction, creatinine > 150mcmol/L) receiving long-term warfarin or heparin therapy received full-dose heparin therapy for more than 48 hours pregnancy symptomatic for pulmonary embolism absence of symptoms within 5 days of presentation geographic inaccessibility which precludes follow-up

Ages Eligible for Study
-----------------
Minimum Age: 0 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: venogram|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| symptomatic DVT and PE in follow-up |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| death |  |  | 
| deep vein thrombosis diagnosed by venography in those |  |  | 
| randomized to that intervention |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
DVT, deep vein thrombosis, pulmonary embolism, PE, venous thromboembolism, VTE, d-dimer, IPG
Parafunctional Habits and Temporomandibular Disorder in Adolescents

Study Overview
=================
Brief Summary
-----------------
The disorders that affect the temporomandibular joint (TMJ) are responsible for the diverse symptoms. Objective: To evaluate whether or not the relationship between signs or symptoms of TMD and presence of harmful habits. The investigators evaluated 244 adolescents enrolled in public school . The investigators used the questionnaire for selection of orofacial pain and temporomandibular disorders, recommended by American Academy of Orofacial Pain to assess the presence or absence of signs and symptoms of TMD.

Detailed Description
-----------------
For the assessment of signs and symptoms of TMD and parafunctional habits, 244 adolescents between 10 and 20 years of age and enrolled in a municipal school system were analyzed. The participants were submitted to the self-explanatory questionnaire for screening recommended by the American Academy of Orofacial Pain for the determination of orofacial pain and TMD. This questionnaire is made up of ten guided questions with yes or no responses to the most frequent signs and symptoms of orofacial pain and TMD. According to the Academy, three or more affirmative responses are an indication of TMD. Patient history and a detailed clinical exam were performed for the assessment of the presence or absence of parafunctional habits. The frequency of signs and symptoms was analyzed and the data were described based on gender and age. The SPSS 12.0 program was used for the statistical analysis and the data were treated using the chi-square test.

Official Title
-----------------
Association Between Parafunctional Habits and Signs and Symptoms Temporomandibular Disorder in Adolescents

Conditions
-----------------
Temporomandibular Disorder, Adolescent Behavior

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age: 10 to 20 years old Exclusion Criteria: no signing a term of informed consent

Ages Eligible for Study
-----------------
Minimum Age: 10 Years
Maximum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Adolescents<br>Adolescents between 10 and 20 years of age and enrolled in a municipal school system. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
temporomandibular disorder, adolescents